{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:40:21Z","timestamp":1793238021043,"version":"4.5.0"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2022,9,1]]},"DOI":"10.1001\/jamapsychiatry.2022.1776","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T15:39:36Z","timestamp":1657726776000},"page":"932","source":"Crossref","is-referenced-by-count":84,"title":["Methadone-Involved Overdose Deaths in the US Before and After Federal Policy Changes Expanding Take-Home Methadone Doses From Opioid Treatment Programs"],"prefix":"10.1001","volume":"79","author":[{"given":"Christopher M.","family":"Jones","sequence":"first","affiliation":[{"name":"National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson M.","family":"Compton","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Han","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Baldwin","sequence":"additional","affiliation":[{"name":"National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora D.","family":"Volkow","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"26","key":"yld220005r2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.15585\/mmwr.mm6526a2","article-title":"Trends in methadone distribution for pain treatment, methadone diversion, and overdose deaths: United States, 2002-2014.","volume":"65","author":"Jones","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"50","key":"yld220005r3","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.15585\/mmwr.mm7050e3","article-title":"Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls: United States, 2019-2020.","volume":"70","author":"O\u2019Donnell","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"yld220005r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108449","article-title":"Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.","volume":"131","author":"Brothers","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"yld220005r5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/00952990.2021.1979991","article-title":"The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era.","volume":"47","author":"Amram","year":"2021","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"6","key":"yld220005r6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/ADM.0000000000000812","article-title":"Reduction in Oregon\u2019s medication dosing visits after the SARS-CoV-2 relaxation of restrictions on take-home medication.","volume":"15","author":"McIlveen","year":"2021","journal-title":"J Addict Med"},{"key":"yld220005r1","unstructured":"Substance Abuse and Mental Health Services Administration. Methadone take-home flexibilities extension guidance. Updated March 3, 2021. Accessed March 15, 2022. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/statutes-regulations-guidelines\/methadone-guidance"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2793744\/jamapsychiatry_jones_2022_ld_220005_1662054878.80084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T15:06:40Z","timestamp":1662563200000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2793744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":6,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.1776","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}